News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|April 1, 2025

Best Practices for Overcoming mCRC Prior Authorization Barriers

Author(s)Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA , Melody Chang, RPh, MBA, BCOP, Nicholas Bouchard, PharmD

Experts discuss effective strategies for navigating the prior authorization process to ensure timely access to third-line therapies for metastatic colorectal cancer (mCRC) and share any success stories.

Episodes in this series

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

What strategies have you found effective in navigating the prior authorization process to ensure timely access to third-line therapies, and can you share any success stories?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

2 experts are featured in this video

Inside the Be-Well Trials: Design, Population, and Patient Selection

ByRaymond Chung, MD,Douglas Dieterich, MD

September 10th 2026

Counseling Vitiligo Patients on Time to Repigmentation

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Trending on AJMC

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

5 August FDA Approvals Marked by Novelty, Pushback

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation